Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD
Patients with CKD often progress to ESRD and develop cardiovascular disease (CVD), yet
available therapies only modestly improve clinical outcomes. Observational studies report …
available therapies only modestly improve clinical outcomes. Observational studies report …
[PDF][PDF] Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD
T Isakova, JH Ix, SM Sprague, KL Raphael, L Fried… - 2015 - academia.edu
Patients with CKD often progress to ESRD and develop cardiovascular disease (CVD), yet
available therapies only modestly improve clinical outcomes. Observational studies report …
available therapies only modestly improve clinical outcomes. Observational studies report …
[引用][C] Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD
T Isakova, JH Ix, SM Sprague, KL Raphael… - Journal of the American …, 2015 - cir.nii.ac.jp
Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD
T Isakova, JH Ix, SM Sprague… - Journal of the …, 2015 - ohsu.elsevierpure.com
Patients with CKD often progress to ESRD and develop cardiovascular disease (CVD), yet
available therapies only modestly improve clinical outcomes. Observational studies report …
available therapies only modestly improve clinical outcomes. Observational studies report …
[引用][C] Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.
T Isakova, JH Ix, SM Sprague… - Journal of the …, 2015 - hsrc.himmelfarb.gwu.edu
"Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 " by Tamara
Isakova, Joachim H Ix et al. Home Search Browse Collections My Account About DC …
Isakova, Joachim H Ix et al. Home Search Browse Collections My Account About DC …
Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD
T Isakova, JH Ix, SM Sprague… - Journal of the …, 2015 - scholars.northwestern.edu
Patients with CKD often progress to ESRD and develop cardiovascular disease (CVD), yet
available therapies only modestly improve clinical outcomes. Observational studies report …
available therapies only modestly improve clinical outcomes. Observational studies report …
Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD
T Isakova, JH Ix, SM Sprague… - Journal of the …, 2015 - pubmed.ncbi.nlm.nih.gov
Patients with CKD often progress to ESRD and develop cardiovascular disease (CVD), yet
available therapies only modestly improve clinical outcomes. Observational studies report …
available therapies only modestly improve clinical outcomes. Observational studies report …
[HTML][HTML] Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD
T Isakova, JH Ix, SM Sprague, KL Raphael… - Journal of the …, 2015 - ncbi.nlm.nih.gov
Patients with CKD often progress to ESRD and develop cardiovascular disease (CVD), yet
available therapies only modestly improve clinical outcomes. Observational studies report …
available therapies only modestly improve clinical outcomes. Observational studies report …
Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.
T Isakova, JH Ix, SM Sprague, KL Raphael… - Journal of the …, 2015 - europepmc.org
Patients with CKD often progress to ESRD and develop cardiovascular disease (CVD), yet
available therapies only modestly improve clinical outcomes. Observational studies report …
available therapies only modestly improve clinical outcomes. Observational studies report …
Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.
T Isakova, JH Ix, SM Sprague, KL Raphael… - Journal of the …, 2015 - europepmc.org
Patients with CKD often progress to ESRD and develop cardiovascular disease (CVD), yet
available therapies only modestly improve clinical outcomes. Observational studies report …
available therapies only modestly improve clinical outcomes. Observational studies report …